ReviewJournal of molecular medicine (Berlin, Germany)2020
Stem cell therapies for retinal diseases: from bench to bedside.
Review in Journal of molecular medicine (Berlin, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Stem cell-based therapies for inherited retinal diseases - Translational advances and clinical evidence: A review.Biomolecules & biomedicine · 2026Review
- Perceptual learning of prosthetic vision using video game training.Journal of vision · 2025Article
- An overview of stem cells and cell products involved in trauma injury.Regenerative therapy · 2025Review
- Potential guidelines for cataract surgery and rehabilitation in visually impaired patients: Literature analysis.Aging medicine (Milton (N.S.W)) · 2024Review
- A virtual patient simulation modeling the neural and perceptual effects of human visual cortical stimulation, from pulse trains to percepts.Scientific reports · 2024Article
- Trim9 regulates the directional differentiation of retinal Müller cells to retinal ganglion cells.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Human retinal secretome: A cross-link between mesenchymal and retinal cells.World journal of stem cells · 2023Review
- Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies.International journal of molecular sciences · 2023Review
- Review
- Recent advances in the therapeutic efficacy of hepatocyte growth factor gene-modified mesenchymal stem cells in multiple disease settings.Journal of cellular and molecular medicine · 2022Review
- Bone marrow-derived mononuclear stem cells in the treatment of retinal degenerations.Neural regeneration research · 2022Review
- Future perspective of stem cell-derived exosomes: Cell-free therapeutic strategies for retinal degeneration.Frontiers in bioengineering and biotechnology · 2022Review
- Cell Replacement Therapy for Retinal and Optic Nerve Diseases: Cell Sources, Clinical Trials and Challenges.Pharmaceutics · 2021Review
- Stem Cell Therapy for Retinal Degeneration: The Evidence to Date.Biologics : targets & therapy · 2021Review
- Interaction Between Mesenchymal Stem Cells and Retinal Degenerative Microenvironment.Frontiers in neuroscience · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the human retina has no regenerative ability, stem cell interventions represent potential therapies for various blinding retinal diseases. This type of therapy has been extensively studied in the human eyes through decades of preclinical studies. The safety profiles shown in clinical trials thus far have indicated that these strategies should be further explored. There are still challenges with regard to cell source, cell delivery, immuno-related adverse events and long-term maintenance of the therapeutic effects. Retinal stem cell therapy is likely to be most successful with a combination of multiple technologies, such as gene therapy. The purpose of this review is to present a synthetical and systematic coverage of stem cell therapies that target retinal diseases from bench to bedside, intending to appeal to both junior specialists and the broader community of clinical investigators alike. This review will only focus on therapies that have already been studied in clinical trials. This review summarizes key concepts, highlights the main studies in human patients and discusses the current challenges and potential methods to reduce safety concerns while enhancing the therapeutic effects.
Indexed as
Identifiers
32794020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.